Insider Transactions in Q2 2022 at Cvs Health Corp (CVS)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
138,654
-6.87%
|
$13,172,130
$95.0 P/Share
|
|
Jun 28
2022
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
138,654
+6.42%
|
$8,596,548
$62.28 P/Share
|
|
May 31
2022
|
Prem S Shah EVP and Group President |
BUY
Grant, award, or other acquisition
|
Direct |
20,671
+50.0%
|
-
|
|
May 31
2022
|
Sreekanth K Chaguturu EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,919
+50.0%
|
-
|
|
May 11
2022
|
Anne A. Finucane Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,384
+19.02%
|
$134,248
$97.99 P/Share
|
|
May 11
2022
|
Edward J Ludwig Director |
BUY
Grant, award, or other acquisition
|
Direct |
165
+0.88%
|
$16,005
$97.99 P/Share
|
|
May 11
2022
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,282
+4.45%
|
$124,354
$97.99 P/Share
|
|
May 11
2022
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,409
+50.0%
|
$136,673
$97.99 P/Share
|
|
May 11
2022
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,358
+5.2%
|
$131,726
$97.99 P/Share
|
|
May 11
2022
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
38
+0.1%
|
$3,686
$97.99 P/Share
|
|
May 11
2022
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
51
+0.05%
|
$4,947
$97.99 P/Share
|
|
Apr 08
2022
|
Prem S Shah EVP and Group President |
SELL
Open market or private sale
|
Direct |
16,954
-6.78%
|
$1,780,170
$105.0 P/Share
|
|
Apr 08
2022
|
Prem S Shah EVP and Group President |
BUY
Exercise of conversion of derivative security
|
Direct |
13,824
+6.27%
|
$857,088
$62.26 P/Share
|
|
Apr 05
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Open market or private sale
|
Direct |
5,941
-15.6%
|
$594,100
$100.0 P/Share
|
|
Apr 04
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Open market or private sale
|
Direct |
55,359
-27.85%
|
$5,535,900
$100.13 P/Share
|
|
Apr 04
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Exercise of conversion of derivative security
|
Direct |
43,327
+22.81%
|
$2,426,312
$56.26 P/Share
|
|
Apr 03
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,179
-0.93%
|
$220,079
$101.09 P/Share
|
|
Apr 03
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,556
-0.48%
|
$359,156
$101.09 P/Share
|
|
Apr 01
2022
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Payment of exercise price or tax liability
|
Direct |
17,388
-15.3%
|
$1,756,188
$101.09 P/Share
|
|
Apr 01
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,214
+20.04%
|
$324,614
$101.09 P/Share
|
|
Apr 01
2022
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,637
-10.62%
|
$670,337
$101.09 P/Share
|
|
Apr 01
2022
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
116,940
-35.76%
|
$11,810,940
$101.09 P/Share
|
|
Apr 01
2022
|
Prem S Shah EVP and Group President |
SELL
Payment of exercise price or tax liability
|
Direct |
22,478
-19.58%
|
$2,270,278
$101.09 P/Share
|
|
Apr 01
2022
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
38,129
-25.88%
|
$3,851,029
$101.09 P/Share
|
|
Apr 01
2022
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77,960
-24.92%
|
$7,873,960
$101.09 P/Share
|
|
Apr 01
2022
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
105,854
-12.65%
|
$10,691,254
$101.09 P/Share
|